One of commercial real estate’s newest breakout stars, the life science sector has been propelled to new heights by the race for COVID-19 vaccines and innovative technology more than 10 years in the making.
 100vw, 300px”/>Robert Albro, CIO & Partner, King Street Properties</p>
<p>Private equity capital, as well as public funding from such organizations as the National Institutes of Health, is pumping billions of dollars into life science research, development and manufacturing. After a record $26 billion in venture capital in 2020, life science investment soared to $39 billion last year, according to J.P. Morgan Chase’s 2022 Annual Outlook on the industry.</p>
<p>Even before this recent surge<strong>, </strong>life sciences had been steadily expanding for years. “Long before the pandemic, this was an industry that had been growing,” said Robert Albro, a partner at King Street Properties, one of the biggest owners and developers of life science properties in the U.S.</p>
<p>Over the past decade, the development of CRISPR—the acronym for a revolutionary gene-editing technology—kicked off a boom that is still going strong. In just a decade, the number of products related to gene and cell therapy soared from zero to 450, while Series A companies are still forming constantly, an important market indicator. Developing therapies has a long timeline; it can take 20 years to go from idea to finished product.</p>
<p><img data-attachment-id=)
One of commercial real estate’s newest breakout stars, the life science sector has been propelled to new heights by the race for COVID-19 vaccines and innovative technology more than 10 years in the making.